Physician profile
Bryan E Waldo
NPI 1982716486
$2,509.98
in general payments reported to CMS, 2019-2025
21 companies · $89.04 in 2025
The $89.04 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $201 · 2021: $416 · 2022: $665 · 2023: $337 · 2024: $470 · 2025: $89.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $81.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.58 |
| Education | $81.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $535.13 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $316.38 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $265.04 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $233.79 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $171.93 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.41 | 2023-2024 | Jardiance |
| Ardelyx, INC. | $123.52 | 2023-2025 | Ibsrela |
| Veran Medical Technologies, INC. | $83.33 | 2020 | |
| Janssen Pharmaceuticals, INC | $78.86 | 2022 | |
| Opko Pharmaceuticals, LLC | $76.18 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $76.16 | 2022-2024 | Purified Cortrophin Gel |
| Fresenius USA Marketing, INC. | $71.16 | 2019-2022 | |
| Novo Nordisk INC | $69.02 | 2022 | |
| Amgen INC. | $49.39 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $42.63 | 2021-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $40.45 | 2024 | Vafseo |
| Glaxosmithkline, LLC. | $37.85 | 2022-2023 | Benlysta |
| Vanda Pharmaceuticals INC. | $34.42 | 2020 | |
| Calliditas Therapeutics US INC. | $22.08 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.72 | 2019 | |
| Lilly USA, LLC | $13.53 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Waldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.